• ZUMA-5: Curative potential of axi-cel in follicular lymphoma

    Axicabtagene ciloleucel was associated with durable responses and long-term survival in relapsed or refractory indolent non-Hodgkin lymphoma.

  • Findings from phase 3 uproleselan study in AML not all negative

    Uproleselan + chemotherapy did not outperform chemotherapy alone for relapsed or refractory AML; but authors saw interesting trends in subgroups.

  • Medical Case: Two faintings in one day

    A man in his 60s enters the ER after two fainting spells on the same day. The previous night he was woken up by severe palpitations. How to proceed?

  • AQUILA: Early intervention with daratumumab extends survival in smouldering MM

    Daratumumab reduced progression to multiple myeloma and prolonged overall survival in patients with high-risk smouldering MM.

  • ATALANTA-1: Promising data for novel CAR T-cell therapy

    The investigational therapy GLPG5101 was associated with high response and a favourable safety profile in relapsed or refractory non-Hodgkin lymphoma.

  • LUNA 3: Rilzabrutinib meets primary endpoint in ITP

    Rilzabrutinib improved efficacy and QoL outcomes over placebo with a favourable safety profile among heavily pre-treated adults with immune thrombocytopenia.

  • Menin inhibitors on the rise in KMT2Ar acute leukaemia

    Revumenib continued to display promising anti-tumour activity among patients with relapsed or refractory KMT2Ar acute leukaemia.

  • PIVOT: Can hydroxyurea improve outcomes in HbSC?

    Hydroxyurea was associated to a reduction in clinical adverse events and improvements in haematological parameters in the phase 2 PIVOT trial.

  • CEPHEUS: Further support for daratumumab-regimens in untreated MM

    Daratumumab plus VRd outperformed VRd alone in MRD-negativity rates for previously untreated multiple myeloma cases ineligible for transplant.

  • New standard-of-care for paediatric B-cell ALL

    Adding blinatumomab to standard chemotherapy improved survival in paediatric patients with NCI standard-risk B-ALL at average or high relapse risk.

  • HIV in France: Updated recommendations from the National Health Authority

    The French health authority updated its recommendations for improving HIV prevention and treatment. Here“s an overview of the main points.

  • AIDS hits young girls particularly hard worldwide

    Despite the decline in new HIV infections in recent decades, UNICEF is concerned about the gender gap in HIV prevalence.

  • ASH 2024: AI and innovative therapies are shaping the future of haematology

    The 66th Annual Meeting of the American Society of Hematology this December is a crucial forum on the latest advances in haematology.

  • Ultra-precision: the Institut Curie uses AI to improve prostate cancer detection

    Artificial intelligence is revolutionising cancer diagnosis, as the Institut Curie steps up its collaboration with Ibex Medical Analytics for post-stroke cancers.

  • Cognitive impairment in rheumatoid arthritis

    New research shows that RA increases the risk of cognitive impairment. Those affected particularly show deficits in memory and executive functions.

  • Vegan food can also be bad for the heart

    For many, a plant-based diet equals health. But is this always so? One study examined ultra-processed, purely plant-based foods' effects on the heart.

  • Therapy options for glioblastoma

    Glioblastoma is an extremely aggressive brain tumour, despite various therapeutic approaches, with a mostly poor prognosis. Which treatment is recommended?

  • EADV 2024 Congress: New perspectives on melanoma

    Recent advances in melanoma diagnosis and treatment emphasise the importance of new biomarkers for early detection and innovative therapies for advanced melanoma.

  • Tamuzimod delivers promising long-term data in ulcerative colitis

    Tamuzimod improved clinical, endoscopic, and histologic outcomes compared with placebo in moderately to severely active UC at week 52.

  • Upadacitinib associated with normalisation of HRQoL in UC

    Upadacitinib induction and maintenance therapy were associated with higher rates of normalisation of health-related quality-of-life (HRQoL) than placebo.

  • 1 |
  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |